Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction - PubMed (original) (raw)
Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction
N L Benowitz et al. Clin Pharmacol Ther. 1980 Jul.
Abstract
Cannabidiol (CBD), 600 mg/day orally for 5 to 12 days, inhibited hexobarbital metabolism in ten subjects. Hexobarbital oral clearance was 36% lower and apparent volume of distribution was 35% smaller, with no change in half-life during CBD. In four subjects who received intravenous and oral hexobarbital, systemic clearance was 36% lower while bioavailability was 10% greater during CBD. Hexobarbital increased fatigue and tremor, impaired eye-tracking performance, and altered the electroencephalogram. Hexobarbital effects were not affected by CBD. Inhibition of metabolism of other drugs should be considered when large amounts of CBD are taken or when CBD is used for therapy.
Similar articles
- Development of tolerance to the prolongation of hexobarbitone sleeping time caused by cannabidiol.
Borys HK, Ingall GB, Karler R. Borys HK, et al. Br J Pharmacol. 1979 Sep;67(1):93-101. Br J Pharmacol. 1979. PMID: 497524 Free PMC article. - Effect of cannabidiol on cytochrome P-450 and hexobarbital sleep time.
Bornheim LM, Borys HK, Karler R. Bornheim LM, et al. Biochem Pharmacol. 1981 Mar 1;30(5):503-7. doi: 10.1016/0006-2952(81)90636-5. Biochem Pharmacol. 1981. PMID: 7225146 No abstract available. - Effect of cannabidiol on cytochrome P-450 isozymes.
Bornheim LM, Correia MA. Bornheim LM, et al. Biochem Pharmacol. 1989 Sep 1;38(17):2789-94. doi: 10.1016/0006-2952(89)90432-2. Biochem Pharmacol. 1989. PMID: 2550010 - Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications.
Perucca E, Bialer M. Perucca E, et al. CNS Drugs. 2020 Aug;34(8):795-800. doi: 10.1007/s40263-020-00741-5. CNS Drugs. 2020. PMID: 32504461 Review. - Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.
Anderson GD, Chan LN. Anderson GD, et al. Clin Pharmacokinet. 2016 Nov;55(11):1353-1368. doi: 10.1007/s40262-016-0400-9. Clin Pharmacokinet. 2016. PMID: 27106177 Review.
Cited by
- Nabiximols effect on blood pressure and heart rate in post-stroke patients of a randomized controlled study.
Rosa GM, Puce L, Mori L, Currà A, Fattapposta F, Porto I, Bragazzi NL, Trompetto C, Marinelli L. Rosa GM, et al. Front Cardiovasc Med. 2022 Oct 28;9:990188. doi: 10.3389/fcvm.2022.990188. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36386386 Free PMC article. - Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review.
Lopera V, Rodríguez A, Amariles P. Lopera V, et al. J Clin Med. 2022 Feb 22;11(5):1154. doi: 10.3390/jcm11051154. J Clin Med. 2022. PMID: 35268245 Free PMC article. Review. - Cannabinoid Therapeutics in Chronic Neuropathic Pain: From Animal Research to Human Treatment.
Campos RMP, Aguiar AFL, Paes-Colli Y, Trindade PMP, Ferreira BK, de Melo Reis RA, Sampaio LS. Campos RMP, et al. Front Physiol. 2021 Nov 30;12:785176. doi: 10.3389/fphys.2021.785176. eCollection 2021. Front Physiol. 2021. PMID: 34916962 Free PMC article. Review. - Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review.
Balachandran P, Elsohly M, Hill KP. Balachandran P, et al. J Gen Intern Med. 2021 Jul;36(7):2074-2084. doi: 10.1007/s11606-020-06504-8. Epub 2021 Jan 29. J Gen Intern Med. 2021. PMID: 33515191 Free PMC article. Review. - The Essential Medicinal Chemistry of Cannabidiol (CBD).
Nelson KM, Bisson J, Singh G, Graham JG, Chen SN, Friesen JB, Dahlin JL, Niemitz M, Walters MA, Pauli GF. Nelson KM, et al. J Med Chem. 2020 Nov 12;63(21):12137-12155. doi: 10.1021/acs.jmedchem.0c00724. Epub 2020 Sep 10. J Med Chem. 2020. PMID: 32804502 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources